TLSI · TriSalus Life Sciences, Inc. · Debt

On February 18, 2025, the closing for the Second Tranche occurred and the Borrower received $10 million pursuant to the Second Tranche. The Second Tranche loan will mature on April 30, 2029. The Third Tranche remains available pursuant to the terms of the Credit Agreement.

Issuer evidence: As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 30, 2024 (the “Initial Closing Date,” and such Current Report on Form 8-K, the “Initial Current Report”), TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “Borrower”) entered into a Credit Agreement (the “Credit Agreement”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “Initial Lender”), as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the lenders. The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $50 million (the “Loan Facility”), of which (i) $25 million was borrowed on the Initial Closing Date and (ii) up to $10 million is available for borrowing on or prior to June 30, 2025 (the “Second Tranche”) and up to $15 million is available for borrowing on or prior to December 31, 2025 (the “Third Tranche”), in each case, subject to the Company satisfying certain revenue requirements.

Supporting evidence: On February 18, 2025, the closing for the Second Tranche occurred and the Borrower received $10 million pursuant to the Second Tranche. The Second Tranche loan will mature on April 30, 2029. The Third Tranche remains available pursuant to the terms of the Credit Agreement.